Hi @Lymmf, I see you & @LesrningEachDay are discussing the...

Hi @Lymmf,

I see you & @LesrningEachDay are discussing the Lightner trials of allogeneic MSCs in fistulizing Crohn’s, I’d just like to add that I think there are likely to be a couple of interim takeaways for MSB, despite the difference in mode of delivery, cell product etc.

First, IMO the safety responses should be of interest. Hopefully they’ll be consistent with MSB’s results to date with Crohn’s patients

Second, the treatment cell actions of assisting the Crohn’s patient’s body in closing a fistula are, as I see it, essentially regenerative in nature. Any positive results for allogeneic cell therapies in this disease may assist MSB e.g. to seek RMAT designation in connection with its own trials.

And, naturally, there may be IP licensing needed from MSB in due course. So I’ll certainly be interested in these trial results & the journal commentary, while we wait for our own.

Cheers